What's Happening?
Colossal Biosciences, a startup focused on de-extinction, is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion. The company, known for its controversial project to resurrect the dire wolf using genetic material
from fossils, has been building technologies that have justified its previous $10.2 billion valuation. Over the past year, Colossal has started generating revenue and has spun out three startups, including Breaking, Form Bio, and Astromech. The company has also offered its conservation technology to the U.S. government and the UAE, which invested $60 million. Colossal plans to spin off its artificial animal womb technology, which could have applications in human fertility treatment.
Why It's Important?
The potential funding round for Colossal Biosciences highlights the growing interest and investment in deep-tech sectors such as longevity tech and alternative energy. The company's work in de-extinction and conservation technology could have significant implications for biodiversity and environmental restoration. If successful, Colossal's projects could lead to the reintroduction of extinct species, impacting ecosystems and potentially creating new markets for biodiversity credits. However, the ethical and ecological implications of de-extinction remain controversial, raising questions about the long-term effects on natural habitats and existing species.
What's Next?
Colossal Biosciences' next steps involve securing the new funding round and advancing its de-extinction projects. The company aims to continue developing its technologies and exploring new revenue streams, such as biodiversity credits. Stakeholders, including environmentalists and policymakers, will likely scrutinize the ethical and ecological impacts of Colossal's work. The company's progress could influence future regulations and public perception of de-extinction and conservation technologies.
